Photo-oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
The actual Demilitarized Zone fence along the Southern Limit Line is completely off-limits to everyone except soldiers, and it is illegal to photograph it. Similarly, the whole estuary of the Han River in the Korean Peninsula is deemed a "Neutral Zone" and is officially off-limits to all civilian vessels. Only military vessels are allowed within this neutral zone. In recent years, Chinese fishing vessels have taken advantage of the tense situation in the Han River Estuary Neutral Zone and illegally fished in this area due to both North Korean and South Korean navies never patrolling this area due to the fear of naval battles breaking out. This has led to firefights and sinkings of boats between Chinese fishermen and South Korean Coast Guard. On 30 January 2019, North Korean and South Korean military officials signed a landmark agreement that would open the Han River Estuary to civilian vessels for the first time since the Armistice Agreement in 1953. The agreement was scheduled to take place in April 2019, but the failure of the 2019 Hanoi Summit indefinitely postponed these plans. The Green Line separating Southern Cyprus and Northern Cyprus is a demilitarised border zone operated by the United Nations Peacekeeping Force in Cyprus operate and patrol within the buffer zone. The buffer zone was established in 1974 due to ethnic tensions between Greek and Turkish Cypriots. The green line is similar in nature to the 38th parallel separating the Republic of Korea and North Korea.
== Overview == The idea of using DNA as a construction material was first introduced in the early 1980s by Nadrian Seeman. The method of DNA origami was developed by Paul Rothemund at the California Institute of Technology. In contrast to common top-down fabrication methods such as 3D printing or lithography which involve depositing or removing material through a tool, DNA Nanotechnology, as well as DNA origami as a subset, is a bottom-up fabrication method. By rationally designing the constituent subunits of the DNA polymer, DNA can self-assemble into a variety of shapes. The process of constructing DNA origami involves the folding of a long single strand of viral DNA (typically the 7,249 bp genomic DNA of M13 bacteriophage) aided by multiple smaller "staple" strands. These shorter strands bind the longer in various places, resulting in the formation of a pre-defined two- or three-dimensional shape. Examples include a smiley face and a coarse map of China and the Americas, along with many three-dimensional structures such as cubes. There are several DNA properties that make the molecule an ideal building material for DNA origami. DNA strands have a natural tendency to bind to their complementary sequences through Watson–Crick base pairing. This allows staple strands to locate the position on the scaffold strand without any external manipulation, leading to self-assembly of the desired structure. The specific sequence of bases in DNA gives the material an element of programmability by determining its binding behavior.
==== Anger at political leaders ==== Resentment increased towards the country's leaders due to the perception that they were not troubled by the food security turmoil faced by ordinary citizens. In August 2008, Zhu Yonglan (祝詠蘭), Director of the State Council Central Government Offices Special Food Supply Centre (CGOSFSC), disclosed in a speech that her firm had been set up in 2004 to source high-quality, all-organic foodstuffs from farms working under the strictest guidelines, for supply to top political leaders, their families and retired cadres.
Sources: en.wikipedia.org
==== Political resurgence ==== Heseltine, who had been seen as an arriviste in his younger days, was now something of a grandee and elder statesman. In 1994 he re-emerged as a serious political player, beginning with his testimony for the Scott Report during the Arms-to-Iraq Inquiry (whose report eventually appeared in 1996). It was revealed that he had refused to sign the Public Interest Immunity Certificates (attempting to withhold evidence from the trial in 1992, on grounds of national security) as demanded by the attorney-general Sir Nicholas Lyell, who advised him that ministers were obliged to sign such a certificate. In fact after half a dozen meetings over the course of a week, and Heseltine insisting on reading Bingham LJ's judgement in the Makanjuola case, Heseltine had agreed to sign a slightly different version of the PII which made clear his reservations. However, this was not picked up on at the trial, nor were Heseltine's concerns – contrary to assurances given to him by Lyell – that some of the documents might be useful to the defence passed on to the trial judge. Nonetheless, his evidence in February 1994 was seen as an attack on Lyell and on the ministers (Kenneth Clarke, his potential rival for the leadership, Rifkind and Tristan Garel-Jones) who had signed the certificates without demur.
== Further reading == Aida, N.; Tamagawa, K.; Takada, K.; Yagishita, A.; Kobayashi, N.; Chikumaru, K.; Iwamoto, H. (April 1996). "Brain MR in Fukuyama congenital muscular dystrophy". American Journal of Neuroradiology. 17 (4): 605–613. PMC 8337276. PMID 8730178. Saito, Fumiaki; Matsumura, Kiichiro (December 2011). "Fukuyama-type congenital muscular dystrophy and defective glycosylation of α-dystroglycan". Skeletal Muscle. 1 (1): 22. doi:10.1186/2044-5040-1-22. PMC 3156645. Fukuyama type muscular dystrophy at NIH's Office of Rare Diseases
It is common in particle physics to use eV/c2 as a unit of mass. Here, eV (electronvolt) is a unit of energy (the kinetic energy of an electron accelerated over one volt, 1.6×10−19 J), and c is the speed of light in vacuum. Energy and mass are related through E = mc2. This definition is useful for a linear particle accelerator when accelerating electrons.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.